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Abstract: Erythrocyte drug encapsulation is one of the most promising therapeutic alternative 
approaches for the administration of toxic or rapidly cleared drugs. Drug-loaded erythrocytes can 
operate through one of the three main mechanisms of action: extension of circulation half-life 
(bioreactor), slow drug release, or specific organ targeting. Although the clinical development 
of erythrocyte carriers is confronted with regulatory and development process challenges, 
industrial development is expanding. The manufacture of this type of product can be either 
centralized or bedside based, and different procedures are employed for the encapsulation of 
therapeutic agents. The major challenges for successful industrialization include production 
scalability, process validation, and quality control of the released therapeutic agents. Advantages 
and drawbacks of the different manufacturing processes as well as success key points of clinical 
development are discussed. Several entrapment technologies based on osmotic methods have 
been industrialized. Companies have already achieved many of the critical clinical stages, thus 
providing the opportunity in the future to cover a wide range of diseases for which effective 
therapies are not currently available.
Keywords: red blood cell, encapsulation method, drug carrier, industrial development, 
clinical use
Introduction
The development of drug encapsulation systems has become an important approach 
to overcome problems of poorly stable, fragile, or potentially immunogenic drugs. 
Over the past two decades, the application of the erythrocyte as drug carrier has gained 
extensive interest. Indeed, this biocompatible vehicle exhibits many advantageous 
features compared to colloidal or synthetic carriers such as liposomes, nanoparticles, 
emulsions, viruses, and pegylated formulations.1 In addition to its long life span in 
circulation (80–130 days), the erythrocyte displays a relatively inert intracellular 
environment and offers specific targeting to the reticuloendothelial system (RES).2–7 
This new therapeutic approach may palliate some of the unmet needs in the fields of 
oncology, rare diseases, and inflammatory conditions.
Technically, there are two main approaches to combine drugs with erythrocytes. 
The first one is by means of forming transient pores in the erythrocyte membrane, thus 
allowing for the drug to enter the erythrocyte. This intraerythrocytic loading method 
is used with the aim to greatly enhance the half-life of the drug and to avoid hyper-
sensitive reactions in patients by shielding the drug from the immune system.8 The 
second strategy consists of coupling the active drug to the erythrocyte membrane, thus 
exposing it at the surface of the cell. Although this latter method has shown efficiency 
in the slow release of drugs,6 it cannot be used to target the RES or to reduce aller-
genic reactions by protecting the drug from the extracellular environment. The present 
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discussion essentially focuses on the encapsulation of drugs 
within erythrocytes, as it meets a greater number of thera-
peutic needs. Different methods have been developed for 
the incorporation of active ingredients within erythrocytes.9 
Among these methods, the most popular are osmotic based, 
electroporation and endocytosis, while other methods, such 
as chemical perturbation of the membrane,10 electric cell 
fusion,11 and lipid fusion,12 remain less explored. The ulti-
mate goal in drug development is to enter the clinic, thus 
requiring large-scale production. The aims of this paper are 
to provide an overview of the most suitable encapsulation 
methods for industrial development and to discuss the main 
key milestones toward marketing approval.
Overview of drug encapsulation 
methods
The development of clinical therapies based on erythrocyte 
carriers necessitates an automation of the encapsulation 
method. In addition, while some conditions need treatments 
that could employ only a few milliliters of processed cells, 
other treatments such as amino acid depletion for tumor 
starvation require the processing of large volumes of blood 
(250–350 mL). These technical constraints deeply reduce 
the spectrum of clinical applications that may emerge from 
laboratory experiments. The following section provides 
an overview of the advantages and disadvantages of each 
encapsulation approach and provides a discussion on the 
most suitable approaches for industrialization.
endocytosis
Ginn et al discovered that endocytosis may be induced in 
mature erythrocytes by drugs of a specific chemical structure.13 
Molecules intercalate passively into the inner membrane of 
the phospholipid bilayer of the erythrocytes. This process ends 
with the formation of vacuoles (containing the drug) within 
the intraerythrocytic compartment. The performance of the 
process is dependent on drug concentration, pH (7.9–8.1), and 
temperature (37°C). However, the method is only suitable 
for the entrapment of cations or anions, which have both 
hydrophobic and hydrophilic groups.14–17 This limitation 
combined with an evident lack of process reproducibility 
makes it incompatible with an industrial development.
Conjugation to cell-penetrating peptides
This method consists of the covalent linking of cell-penetrating 
peptide (CPP) to the molecule of interest via a disulfide link-
age. The transfer of the peptide across the cell membrane is 
made through a process of protein transduction, delivering 
the therapeutic molecule within the cell. Different types of 
cells can internalize the CPP-conjugated molecule. This 
process was specifically applied to erythrocytes with the 
encapsulation of CPP-conjugated l-asparaginase, an enzyme 
that displays therapeutic benefits in the treatment of acute 
lymphoblastic leukemia.18,19 Within the erythrocyte, CPP is 
dissociated from l-asparaginase via reduction in disulfide 
bonds by intraerythrocytic glutathione and reductases. 
Although this entrapment method presents the advantage of 
being noninvasive toward the erythrocyte, its use for clinical 
applications may be compromised by several aspects. First, 
it has not been demonstrated that CPP-mediated entry is 
irreversible and CPPs have been found to be enriched in 
the extracellular medium supporting a reversibility of the 
phenomenon. Second, the reproducibility of encapsulation 
is highly dependent on the cellular reductase activities that 
may be difficult to handle at the industrial level. Third, 
although the last generation of CPP such as low molecular 
weight protamine appears to be nonimmunogenic and less 
toxic, this safety aspect needs careful consideration in view 
of chronic exposure in patients.
Dimethyl sulfoxide osmotic pulse
This method was essentially used for the incorporation 
of inositol hexaphosphate (IHP), an allosteric effector of 
hemoglobin.20,21 The method is performed using four steps: 
first, dimethyl sulfoxide (DMSO) is added to red blood 
cells (RBCs) to raise the osmolality of suspension (between 
1,000 mOsmol/kg and 1,500 mOsmol/kg, depending upon 
DMSO concentration). Then, erythrocytes are diluted with an 
isotonic solution of the drug. This induces a rapid decrease 
in DMSO concentration in the extracellular compartment 
and a transient gradient across the erythrocyte membrane. 
This gradient is accompanied by an influx of water and drug 
loading until equilibrium between intra- and extraerythrocytic 
DMSO concentrations is reached. This mechanism is possible 
because the DMSO escape from the cell is slower than the 
entry of water into the cell. The DMSO method results not 
only in highly loaded RBCs but only in a small fraction of 
cells (a total of 9%–25%).22 To isolate this “IHP-enriched” cell 
fraction, some researchers conducted a Percoll separation but 
this technique is time-consuming and costly, and therefore, this 
technique may be only applicable at the laboratory scale.
electroporation
This method has been applied to numerous living cells 
by Tsong23 and by Tsong and Kinosita.24 It consists of 
generating an electric shock to induce erythrocyte membrane 
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permeability in isotonic solutions. The potential difference 
created across the membrane leads to the formation of pores 
in the erythrocyte membrane. Ions are rapidly distributed 
between the intra- and extracellular compartments causing 
erythrocyte swelling and drug entry. This method has been 
successfully used for the encapsulation of several molecules 
and macromolecules in human erythrocytes.25–27 In 1995, 
Nicolau et al developed a large-scale, continuous-flow elec-
troporation system to load IHP.28–30 Unfortunately, the device 
was not suitable for processing large volumes of blood (only 
20–50 mL) which may limit clinical application.
Osmotic-based methods
On the contrary to the methods mentioned earlier, osmotic-
based methods present flexible process parameters allowing 
the development of specialized equipment capable of handling 
large volumes of blood. These methods are all based on the 
osmotic pressure difference between the inside and outside 
of the erythrocyte. Among the three existing methods (hypo-
tonic preswelling, hypotonic dilution, and hypotonic dialy-
sis), the hypotonic preswelling and the hypotonic dialysis 
processes remain the more scalable ones. The common 
sequential steps to obtain lysed–resealed erythrocytes by 
these techniques include: 1) isotonic washings of cells, 
2) contact with hypotonic medium permitting pore opening 
in the erythrocyte membrane diffusion of drug in the intra-
cellular compartment, and 3) after hypertonic/iso-osmotic 
buffering, resealing of pore restoration of isotonicity. The 
concept and the robustness of osmotic methods have led to 
several companies embarking on the industrial development 
of drug-loaded human erythrocytes and the development of 
apparatus suitable for clinical applications.
Hypotonic preswelling
This two-step technique is based on the controlled swelling of 
erythrocytes. First, cells are washed with slightly hypotonic 
buffered solution. Under these conditions, the most fragile 
cells hemolyze and the remaining intact ones swell until 
reaching roughly 150% of their initial volume. After 
centrifugation, the supernatant is discarded and the pellet of 
preswelled RBCs is isolated. In the second step, a hypotonic 
aqueous solution of the drug is prepared and carefully added 
to the washed erythrocytes in small volumes. Between each 
drug addition step, the suspension is centrifuged. The process 
is continued until a lysis point is reached (disappearance of 
distinct frontier between packed cells and the supernatant 
after centrifugation). The slow process of swelling results 
in a good retention of cytoplasmic components. RBCs are 
then resealed by adding a calculated volume of isotonic 
buffer and then incubation at 37°C.31 Small molecules 
have been successfully encapsulated at the laboratory scale 
using this method.32,33 In 1998, Magnani et al developed a 
medical device for erythrocyte loading termed the “Red Cell 
Loader” (proprietary technology of EryDel S.p.A., Urbino, 
Italy). The method of entrapment is based on the “preswell” 
of erythrocytes with two sequential hypotonic dilutions of 
washed erythrocytes followed by a concentration step using 
a hemofilter. The operation takes roughly 2 hours.34 The 
process is usually performed in the blood transfusion service 
of the hospital using homologous or autologous erythrocytes 
and specific disposable kits depending on the procedure to 
apply. By allowing rapid administration of loaded eryth-
rocytes to the patient, the use of Red Cell Loader avoids 
problems of in vitro drug leakage. This strategy may be 
useful for the administration of drugs for which slow and 
prolonged release into circulation is needed.35 The limita-
tion of this industrial procedure is the volume of processed 
erythrocytes which has been standardized to only 50 mL 
in order to prevent discomfort of patients (patents WO 
2011/135429 A1 and WO 2011/135431 A1).36 Such low 
volumes may not be suitable for enzyme therapies employed 
for the purpose of systemic detoxification.
Hypotonic dialysis
This method consists of using semipermeable membranes for 
drug incorporation. In the majority of cases, the molecule 
to be entrapped has a molecular weight greater than the 
cutoff of the dialysis membrane and is added to erythrocyte 
suspension at the beginning of the process. Technically, 
there are two main ways to perform hypotonic dialysis. The 
first method uses dialysis bags. The dialysis bag containing 
a buffered suspension of erythrocytes is immersed into 
10–20 volumes of a hypotonic buffer and gently mixed for 
at least 1 hour to allow pore opening and drug entry.37 This 
procedure has been successfully used clinically. Over a 
period of 17 years, a patient suffering from adenosine deami-
nase (ADA) deficiency was treated at 2–3 weekly intervals 
with ADA-loaded autologous erythrocytes (prepared in 
dialysis bags). The treatment proved to be metabolically 
and clinically effective.38 The same process was used to 
load thymidine phosphorylase (TP), and therapeutic benefits 
were observed in patients affected with mitochondrial 
neurogastrointestinal encephalopathy (MNGIE).39 Both 
ADA-RBCs and TP-RBCs were manufactured according to 
the current good manufacturing practice (cGMP) guidelines 
in a pharmaceutical environment. However, in order to reach 
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industrial manufacturing, this loading process using dialysis 
bags requires optimization in terms of shelf life, automation, 
and large-scale feasibility.
The second method, which is far more rapid and effec-
tive, is little described in the literature. With this method, 
the dialysis bag is replaced by a dialysis cartridge composed 
of multiple hollow fibers (hemodialyzer) and is much more 
convenient for treating large volumes of blood. The buff-
ered RBC suspension containing the drug is introduced 
into the blood compartment of the dialyzer by the means of 
peristaltic pump. Drug entry into erythrocytes is performed 
by contact of the cell suspension with a hypotonic buffer 
running at countercurrent into the hemodialyzer.40,41 In 
1982, Ropars et al patented an automated process for the 
internalization of drugs into erythrocytes using the encap-
sulation of IHP as an illustration.42 Although the apparatus 
guarantees pyrogen-free and sterile erythrocyte suspensions, 
it was not tested in the clinic. In 2006, Godfrin optimized 
this process and developed an apparatus termed the “ERY-
caps®” for industrial application (proprietary technology of 
ERYTECH Pharma, Lyon, France).43 On the contrary to 
the Red Cell Loader described previously, the ERYcaps® 
provides drug-loaded RBCs prepared from homologous 
erythrocytes in a dedicated cGMP pharmaceutical unit. 
The whole process takes roughly 3 hours and erythrocyte 
pellets of 250–350 mL can be treated (patented process).43 
This strategy can be successfully used to prolong the circu-
latory half-life of active macromolecules compared to that 
of erythrocyte half-life.
In the “Overview of drug encapsulation methods” section, 
we made an inventory of existing loading procedures and 
discussed the feasibility of industrial transposition. The argu-
ments were put forward to show that osmotic-based methods 
(preswelling and hypotonic dialysis) are the best candidates 
for industrial development, providing greater ease to build 
customized and automated machinery as compared to other 
encapsulation methods. Several companies have invested in 
this innovative technology with the aim of offering patients 
the benefits of erythrocytes as drug carriers.
Focus on promising therapeutic 
applications
Although the erythrocyte is anucleate, it remains a living cell. 
Therefore, the success of drug encapsulation is conditioned 
by two main biological parameters:
1. The diameter of pores opened in the erythrocyte 
membrane.
2. The chemical nature of the erythrocyte membrane.
In our experience, the most “incorporable” molecules 
are macromolecules ranging roughly from 1,000 Da to 
500,000 Da. The encapsulation of small molecules is associ-
ated with an increased probability of drug leakage unless the 
drug presents phosphate groups that facilitate drug retention 
within the cell, for example, IHP. Therefore, drug-loaded 
erythrocytes tend to be naturally designed to offer potential 
therapies for metabolic diseases and enzyme deficiencies, 
needing the encapsulation of macromolecules, rather than 
for infectious diseases or hepatic metastases for which 
reference drugs are often nonencapsulable small molecules 
(ie, nonpolar antibiotics and 5-fluorouracil, respectively). 
In addition, the mechanism by which the erythrocytes are 
exploited is very important for successful industrial develop-
ment. There are three major possible uses of erythrocytes as 
drug carriers (Figure 1).
Drug-loaded erythrocytes as circulating 
“bioreactors”
The objective of using erythrocytes as bioreactors is the 
clearance of undesired molecules from the bloodstream. For 
instance, l-asparaginase-loaded RBCs were developed for 
the degradation of plasmatic asparagine. It is the simplest 
application and the more natural one since it does not require 
any cell treatment in addition to the loading procedure. In this 
system, the erythrocyte is actively involved in the efficacy 
of the medicinal product via:
1. An active transport of the substrate (ie, asparagine) 
through specific membrane transporters.44,45
2. A protection of the active ingredient (ie, l-asparaginase) 
against antidrug antibodies and anaphylactic reactions.
Drug-loaded erythrocytes as a 
slow-release system
The use of erythrocytes as a controlled release of drug is 
predominantly devoted to small molecules that are minimally 
retained within erythrocytes and progressively leak from the 
cell into the plasmatic compartment. The major problem 
with the slow release is that once encapsulation is performed, 
the molecule may escape rapidly. To address this problem, 
Magnani et al patented a procedure that retains small drugs 
within the intra-erythrocytic compartment by means of high-
affinity intracellular components.46 Immunophilin proteins 
that noncovalently bind to immunosuppressive drugs are 
entrapped within erythrocytes to increase drug retention.47 
Although clever and suitable for industrial application, this 
method is restricted to molecules that are ligands of proteins. 
Another possibility is to encapsulate a prodrug that will be 
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Figure 1 Schematic of possible therapeutic applications of erythrocyte drug carriers: (1) as a circulating bioreactor, (2) for controlled drug release, and (3) as for targeting ReS.
Abbreviations: ReS, reticuloendothelial system; RBCs, red blood cells.
progressively cleaved by intraerythrocytic enzymes to deliver 
the active drug. This method has been successfully applied 
to the entrapment of dexamethasone-21-phosphate, the active 
drug (dexamethasone) being released after the removal of 
the phosphate group by intraerythrocytic esterases. For other 
drug classes, researchers have resorted to crosslinking agents 
such as glutaraldehyde (GA) and bis(sulfosuccinimidyl) 
suberate (BS3) to rigidify the erythrocyte membrane and 
reduce leakage.15,48–51 The resulting chemically modified 
erythrocytes present a marked decrease in deformability and 
membrane fluidity. This membrane alteration reduces eryth-
rocyte biocompatibility and leads to their rapid elimination by 
the monocyte–macrophage system of the spleen.52 Thus, the 
employment of crosslinkers to induce “slow drug release” is 
not recommended for clinical use. Recently, the coating of 
loaded erythrocytes with biocompatible polyelectrolytes (poly-
l-lysine hydrobromide and dextran sulfate) has been explored 
to counterbalance the inability of erythrocytes to control 
protein and drug release.53 It was demonstrated that adjusting 
the number of polyelectrolyte layers could regulate the release 
profile of the encapsulated protein. However, the industrial 
feasibility of polyelectrolyte layers may be an issue.
Drug-loaded erythrocytes for ReS targeting
The third application consists of using RBCs to target the 
RES, also referred to as the monocyte–macrophage system. 
Like many other cells, erythrocytes express phosphatidyl 
serines when entering apoptotic phase which act as cell 
surface signals for recognition by phagocytic cells. After 
erythrocyte engulfment by the macrophage, the encapsu-
lated protein is degraded into the lysosomal compartment 
in order to be presented to the immune cells. The senescent 
RBC is thus an excellent antigen carrier for vaccination 
or tolerance induction. Ex vivo, the erythrocytes may be 
artificially pre-aged to increase their uptake by phagocytic 
cells. The methods of pre-aging can be enzymatic, thermal, 
or chemical. In preclinical studies, the use of neuraminidase 
enzyme to remove sialic acids from erythrocyte membranes 
in order to induce cell senescence has been explored.54 The 
heterogeneity of the enzymatic activity, however, may lead 
to nonreproducible drug-loaded suspensions. Heat treatment 
(ie, 42°C for 90 minutes or 48°C for 30 minutes) has also 
been proposed for the pre-aging of processed cells by energy 
depletion.54,55 As previously mentioned, crosslinkers may 
also be used to target the spleen and the liver. GA reacts 
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extensively with proteins in the erythrocyte membrane. The 
resulting erythrocytes are characterized by an extreme rigidity 
compromising their use for in vivo applications. Using BS3 
agent, the treatment is less harsh and leads to the crosslinking 
of specific proteins such as Band 3.56 BS3-treated erythrocytes 
are less rigid than GA-treated cells and thus appear more 
suitable for clinical use. It is also possible to enhance eryth-
rocyte senescence by using a BS3/ZnCl
2
 combination which 
is described to induce autologous IgG binding and comple-
ment fixation (opsonization), thus favoring the phagocytosis 
of ZnCl
2
/BS3-treated cells by macrophages.57
The two main applications of the RES-targeting strategy 
by erythrocytes are as follows:
1. The delivery of small chemical entities such as antiret-
roviral nucleoside analogs.58,59
2. The encapsulation of antigens for vaccination or tolerance 
induction.41,55,60–64
Because of protein degradation by lysozyme, the delivery 
of intact therapeutic proteins is more challenging. However, 
among possible applications of delivery with large macro-
molecules, one can cite enzyme replacement therapies for 
lysosomal storage diseases for which the targeted compart-
ment is the lysosome itself.
Erythrocyte carriers present a large number of therapeu-
tic applications. This innovative technology is expected to 
alleviate treatment regimens and to reduce hospitalization 
frequency and duration.65 The success of the pharmaceutical 
development essentially depends on how well the compa-
nies heighten the clinician community’s understanding of 
this exciting technology and stimulate its market uptake. 
At present, the therapeutic applications of RBCs for con-
trolled drug release as circulating bioreactors are undoubtedly 
the two best approaches to accelerate market entry. The use 
of the erythrocyte carrier for vaccination or tolerance will 
require specialized development steps.
Product quality
Cell material source
Drug-loaded erythrocytes can be prepared from autologous 
or homologous donated blood. Autologous erythrocyte 
processing is usually performed using bedside medical 
devices. In the case of homologous transfusion, the cell mate-
rial source consists of erythrocyte pellets provided by blood 
banks. Erythrocytes are prepared from whole blood collected 
from healthy donors and subjected to leukocyte depletion 
(criterion of acceptance ,5×106/unit). The appropriate 
erythrocyte pellet is selected according to patient’s ABO blood 
type and valid irregular antibody screening. In order to avoid 
the processing of pellets that present storage lesions, erythro-
cyte units of ,10 days on the day of processing are used.
Qualification of the drug to be encapsulated
Since the manufacturing process of drug-loaded erythro-
cytes is particularly new for regulatory bodies, existing 
guidelines are not well adapted and it is difficult to qualify 
the status of both intermediates and final products. The drug 
to be encapsulated may be considered as an active phar-
maceutical ingredient (API) starting material. If the drug 
is already on the market, all pharmaceutical information 
will be available on a certificate of analysis provided by the 
manufacturer. In other cases, it is the responsibility of the 
company developing the erythrocyte carrier to manufacture 
the active drug in compliance with cGMP and to ensure its 
full characterization with analytical procedures meeting all 
the requirements laid down in ICH guidelines Q2A, Q2B, 
Q3A, Q3C, and Q6A.66
Scale-up
The scaling-up process from laboratory scale to clinical 
production may be critical in the manufacturing of drug-
loaded erythrocytes. The aim of the scale-up process in 
erythrocytes manufacturing is to encapsulate the therapeutic 
substance in an efficient and fast way to produce drug-loaded 
erythrocytes with good yield. Although drug-loaded eryth-
rocytes are biological products, the process can be long and 
difficult.
Manufacturing process
The manufacturing of drug-loaded erythrocytes can be either 
centralized or performed in the clinic. In each case, all safety 
measures must be taken to maintain the sterility of the cell 
suspension, through the use of sterile disposable materials 
and closed circuit procedures. In addition, apparatus such as 
the Red Cell Loader is required to be in compliance with the 
European Medical Devices Directive 93/42. For the central-
ized manufacturing of loaded erythrocytes, the facility must 
be maintained under A/B air grade and fully compatible with 
current pharmaceutical requirements.
The regulatory aspects at European level are reflected 
in European Medicines Agency guidelines for advanced 
therapy medicinal products.67 In addition, cGMPs for the 
manipulation of cells for clinical use are also based on the 
Code of Federal Regulations, 21 Part 211 through the US 
Food and Drug Administration Tissue Reference Group and 
the Japanese guidelines for the use of medical devices based 
on human autologous cells.68–71
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The irradiation of final product to lower the risk of graft-
versus-host disease appears to be unnecessary due to the 
significant reduction in leukocyte numbers achieved with 
the manufacturing process (80-fold leukocyte reduction as 
compared to classical stored erythrocytes using ERYcaps® 
manufacturing process).
Product storage
Storage properties may differ depending on the preservative 
solution and the container used for final product. The stor-
age containers commonly used for erythrocyte products are 
plasticized polyvinyl chloride bags. Care should be taken to 
select bags that contain plasticizers which are essentially non-
extractable in blood. In order to strengthen product safety, the 
evaluation of extracted substances from selected final container 
would provide more confidence with regard to the medical use 
of the erythrocyte product. Unlike long shelf-life drugs, drug-
loaded erythrocytes must be rapidly administered to patients 
to avoid storage-induced RBC degradation. The nature of the 
solution used to preserve the product plays a major role in 
the quality and stability of modified cells. Although SAGM 
(saline, adenine, glucose, and mannitol) is the most widely 
used erythrocyte storage solutions, it has not been licensed 
by the US Food and Drug Administration, and hence is not 
used in the USA. Other solutions have been developed and 
commercialized: AS-1, AS-3, AS-5, MAP, erythrosol-4, PAG-
GGM, and PAGGSM, some of which have been demonstrated 
to reduce hemolysis upon storage as compared to SAGM.72 
Recently, an experimental filter has been developed to improve 
the quality of the erythrocytes during storage.73
in vitro characterization of product
In the past decade, many cellular therapeutics have failed to 
obtain marketing approval due to an inadequate characteriza-
tion of the end product.74 Therefore, it is extremely important 
to conduct an extensive characterization during clinical 
development in order to consolidate knowledge of the product 
and to provide regulatory authorities with reassurance with 
regard to its safety. As drug-loaded erythrocytes are consid-
ered as new products, the safety and quality questions raised 
are essentially related to the impact of manufacturing process 
on erythrocyte functionality and viability. To answer those 
questions, a battery of laboratory tests must be performed on 
the product to catalog any physical or biochemical changes in 
the erythrocyte as a result of processing. Changes that usually 
occur following the osmotic entrapment process include 
erythrocyte hemolysis, loss of intraerythrocytic components, 
reduction in erythrocyte membrane plasticity, and decrease 
in mean cell volume. The manufacturing process should not 
lead to changes .20% in order to retain as much as possible 
the integrity of the erythrocytic cell.
The loss of intracellular material upon processing may 
be evaluated with the assessment of cellular hemoglobin 
content. Changes in erythrocyte deformability may be 
explored by ektacytometry, a technique that measures the 
elongation of suspended RBCs subjected to a range of shear 
stresses.75 It has been reported that human erythrocytes 
loaded with IHP-RBCs have a reduced deformability and 
aggregability and increased viscosity as compared to normal 
erythrocyte suspension at the same hematocrit.76 The osmotic 
fragility may be determined to have an in vitro evaluation 
of erythrocyte viability, though it may not be predictive of 
product in vivo behavior.77 It is also important to measure 
concentrations of essential metabolites such as adenosine 
triphosphate and glucose and to have recourse to supplemen-
tation in case of deficiencies in the final product. In addition, 
erythrocyte functionality (oxygen-carrying capacity) should 
also be controlled with the setup of specific tests including 
plotting the oxygen dissociation curve (for the evaluation of 
P50 value and arteriovenous oxygen saturation differences) 
and the assay of intraerythrocytic content of 2,3-diphospho-
glycerate (natural allosteric effector of hemoglobin).78 If the 
measured values are significantly decreased as compared to 
physiological values, a “rejuvenation” procedure should be 
included in the process.
Clinical batch release
For clinical batch release, it is crucial to conduct a drug assay 
and to measure extracellular hemoglobin level to guarantee 
the quality and the safety of the product at the time of patient 
infusion. In the case of centralized manufacturing, the 
clinical batch is characterized on-site in the quality control 
laboratory. If the product conforms to specifications, it will 
be released by the head pharmacist and sent to the hospital 
as a ready-to-use blood unit with a 72-hour shelf life.39 In the 
case of bedside apparatus, each hospital using the technology 
is under obligation to validate analytical methods and to have 
access to qualified personnel in order to be able to release 
the clinical batch. For products prepared from autologous 
erythrocytes, the major hurdle is the short time frame from 
blood collection to reinfusion leaving very little time for 
characterization.
in vivo characterization of product
Because of the difficulty of extrapolating in vitro results, 
in vivo studies remain the gold standard to evaluate the 
Drug Design, Development and Therapy 2016:10submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
672
Bourgeaux et al
quality of new erythrocyte products. The primary test is 
based on the evaluation of percentage of red cells recovered 
24 hours following transfusion. Indeed, poorly viable cells are 
usually removed from blood circulation within that period of 
time. The method usually recommended to assess the survival 
of stored RBCs is the sodium [51Cr] chromate radiolabeling 
technique.79,80 However, this method requires pretransfusional 
manipulations of cells including room temperature incubation 
and successive washings that may damage the blood product. 
In addition, it was reported that [51Cr] chromate elutes at 
a rapid rate during the 24–48 hours following transfusion 
leading to an underestimation of 24-hour cell survival as 
well as erythrocyte life span (3.5-fold reduction in life 
span in baboon as compared to nonradioactive method).80,81 
Therefore, a nonradioactive and noninvasive method is 
preferred. In 2003, Zeiler et al exploited antigen mismatching 
for the quantification of different RBC populations by flow 
cytometry.82 Thus, drug-loaded erythrocytes prepared with 
RhD(-) erythrocytes and transfused to RhD(+) patients could 
easily be detected by flow cytometry using anti-antigen D 
antibodies. No pretransfusional treatment is required. In 
addition, withdrawn blood samples can be directly labeled 
with fluorochrome-coupled primary antibodies avoiding cell 
loss due to washings/centrifugation steps and thus increasing 
accuracy of method.
According to published data, both autologous erythrocytes 
loaded with dexamethasone-21-P (prepared with Red Cell 
Loader) and homologous RBC loaded with l-asparaginase 
(prepared with ERYcaps®) have 24-hour survival above the 
recommended threshold of 75%. In addition to the 24-hour 
survival, the evaluation of the pharmacokinetic (PK) and the 
pharmacodynamic parameters is requested as for any other 
drug. This includes the determination of in vivo half-life as 
well as the monitoring of drug efficiency. As a result of prod-
uct novelty, very few data are published on the PK parameters 
of drug-loaded erythrocytes. The half-life of l-asparaginase 
encapsulated into erythrocytes was reported to be ∼28 days.65 
Erythrocytes loaded with dexamethason-21-P was slightly 
lower at 23 days.34 These values are close to values found for 
conventionally stored erythrocytes (28±2 days).
The industrial challenge
Companies developing erythrocyte carriers face three key 
challenges.
A high-performance and reproducible 
process
One of the main challenges for industrialization success is to 
develop a reproducible loading procedure. For that purpose, it 
is indispensable to take into account the source cell variability. 
Indeed, significant differences in erythrocyte resistance to 
lysis (osmotic fragility) may be observed between batches of 
erythrocyte starting material (from 2 g/L to 5 g/L) depending 
on multiple parameters such as donor age or blood storage 
conditions. In order to avoid substantial differences in quality 
of end products and to guarantee a consistent encapsulation 
rate, process operating conditions should be adjusted (ie, 
erythrocyte flow rate and osmolality of buffers) according to 
the osmotic fragility of the initial donor erythrocyte pellet.83 
In addition, in the patented manufacturing process based on 
hypotonic dialysis (WO 2006/016247), it was postulated that 
the osmotic fragility should not be measured on the initial 
RBC pellet but on washed RBCs in the presence of the drug 
of interest. Indeed, this latter suspension is fully representa-
tive of the suspension intended for lysis–resealing procedure 
and allows consideration of the possible toxic or protective 
effects of drug toward the erythrocytic cell.43 Considering 
the application of carrier erythrocytes for human therapies, 
quality-by-design (QbD) criteria should also be considered 
to identify critical points and reduce risks during the manu-
facturing processes.
Low cost of goods
The price of the API starting material may vary widely 
depending on whether the drug is under patent protect ion, 
commercially available as a reference drug or generic form, 
or whether it requires cGMP manufacturing. Indeed, for the 
encapsulation of commercially unavailable macromolecules, 
the outsourcing of cGMP manufacturing to a contract 
manufacturing organization may bring an additional 
cost of ∼€500k–1,500k to product development. This may 
significantly impact on the price of the final drug-loaded 
product and compromise project viability. Moreover, addi-
tional costs such as infrastructure costs should be considered. 
This forces industry to reach high encapsulation rates to 
minimize the waste of API starting material and to render 
products more profitable. According to published data, the 
ERYcaps® and the Red Cell Loader encapsulating procedures 
present similar encapsulation rates of ∼30%.34,65 Improving 
this yield should reduce the cost of goods.
An efficient logistic
Companies should develop efficient logistics to enable 
personalized medicine requirements to be met. The stability 
of the product is a key parameter to manage both clinician 
demand and manufacturing constraints. The security and 
the traceability of the cold-chain distribution also constitute 
major challenges, especially for centralized manufacturing 
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with a supply chain covering international distances. 
Specialized logistics companies are now providing tempera-
ture sensors that detect and transmit data on temperature upon 
product shipment.
Current clinical status of 
erythrocyte carriers
Due to the leaders in the industrial development of erythro-
cytes carriers, the technology is now reaching the late stage 
of pharmaceutical development. Companies have end-stage 
products in their pipeline and sufficient clinical evidence 
to overcome the last but not least step toward marketing 
approval.
ERYTECH Pharma based in (Lyon, France) devel-
oped a therapeutic solution (GR-ASPA) for the treatment 
of acute lymphoblastic leukemia: positive results were 
obtained in children and adults (Phase I/II8 and randomized 
international Phase III [NCT01518517] studies) as well as 
in elderly patients (Phase II trial).84 Patients administered 
with homologous erythrocytes loaded with l-asparaginase 
(GR-ASPA) showed a reduction in the number and the 
severity of allergic reactions as compared to the free 
enzyme.8,65 A Phase I clinical study was launched in the USA 
(NCT0181010705). Other clinical trials were initiated in 
Europe to extend GR-ASPA therapeutic applications. A trial 
IIb is ongoing in acute myeloid leukemia (NCT01810705). 
Preclinical animal studies showed the potential therapeutic 
benefit of this product in solid tumors. An orphan drug 
designation (ODD) status was granted for pancreatic cancer 
and a Phase I escalade dose trial was recently completed 
(NCT01523808). An early-stage product named ENHOXY® 
has also been developed as a powerful oxygen enhancer in 
the fields of sickle cell anemia (ODD granted in 2012) and 
more generally hypoxia-related diseases.85
EryDel, in Italy, has developed EryDex, a system to 
deliver dexamethasone at stable low systemic levels over 
an extended period of time. The benefits of treatment 
were demonstrated in the frame of clinical pilot studies 
in patients with chronic obstructive pulmonary disease,86 
cystic fibrosis,87 ulcerative colitis, and Crohn’s disease.88 
More recently, the product presented a great therapeutic 
interest for ataxia telangiectasia, a rare autosomal recessive 
neurological disorder with high mortality.89 A pilot Phase II 
trial demonstrated statistically significant efficacy of product 
(NCT01255358).90,91 The product obtained ODD status in 
2013. A Phase I PK study of EryDex is ongoing in the USA, 
and a pivotal Phase III trial should be initiated soon.
Orphan Technologies Ltd (Rapperswil, Switzerland), is a 
newly created company dedicated to the treatment of rare and 
ultrarare diseases. The company recently acquired the license 
for developing OT-15-MNGIE (TP-loaded erythrocytes for 
the treatment of MNGIE) and OT-81-ADA-SCID (ADA-
loaded erythrocytes) for the treatment of severe combined 
immunodeficiency. Both products are currently administered 
to humans under compassionate use and have not yet entered 
Phase I clinical trials.
Conclusion
This review addresses the use of resealed erythrocytes 
for clinical application. Although the field of potential 
therapeutic applications described by laboratory experi-
ments is broad, the pathway to the clinics is long and it is 
therefore important to address both industrial feasibility 
and safety considerations early on. In the present paper, we 
described the most commonly used entrapment methods. 
All procedures have benefits and drawbacks. Osmotic-based 
methods are associated with high process performance and 
reproducibility and are therefore the most suitable ones for 
industrial development. The main daunting challenges for 
manufacturing success include production scalability, pro-
cess validations, and quality control of released therapeutic. 
Several companies embarked on the development of drug-
loaded erythrocytes with specific apparatus. The Red Cell 
Loader and the ERYcaps® are two promising technologies 
with complementary therapeutic applications. The Red Cell 
Loader was successfully used for controlled drug release. 
Enzyme-loaded erythrocytes through the ERYcaps® have 
already proven clinical therapeutic benefits as compared to 
the free enzyme, reducing the dosage amount and frequency 
and improving patients’ quality of life. The use of the 
erythrocyte as drug carrier is a fundamental advancement 
in the current exploitation of blood and may be applicable 
in medical fields for which no effective therapy is currently 
available.
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